Tenofovir amibufenamide

Tenofovir amibufenamide (HS-10234), a Tenofovir prodrug, is an orally active antiviral agent. Tenofovir amibufenamide inhibits HBV, and can be used for chronic hepatitis B (CHB) study[1][2].

Product Specifications

CAS Number

[1571076-26-0]

Product Name Alternative

HS-10234

UNSPSC

12352005

Target

HBV

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/tenofovir-amibufenamide.html

Purity

99.67

Solubility

DMSO : 200 mg/mL (ultrasonic)

Smiles

C[C@@H](OC[P@](OC1=CC=CC=C1)(NC(C)(C)C(OC(C)C)=O)=O)CN2C3=NC=NC(N)=C3N=C2

Molecular Formula

C22H31N6O5P

Molecular Weight

490.49

References & Citations

[1]Zhihong Liu, et al. Randomised clinical trial: 48 weeks of treatment with tenofovir amibufenamide versus tenofovir disoproxil fumarate for patients with chronic hepatitis B. Aliment Pharmacol Ther. 2021 Nov;54 (9) :1134-1149.|[2]Hong Zhang, et al. Randomised clinical trial: safety, efficacy and pharmacokinetics of HS-10234 versus tenofovir for the treatment of chronic hepatitis B infection. Aliment Pharmacol Ther. 2021 Jan;53 (2) :243-252.|[3]Hong X, et al., Improved pharmacokinetics of tenofovir ester prodrugs strengthened the inhibition of HBV replication and the rebalance of hepatocellular metabolism in preclinical models. Front Pharmacol. 2022 Aug 29;13:932934.